|
Number of diseased vessel
|
NS
|
|
One, n (%)
|
80 (42.3)
|
2 (22.2)
| |
|
Two, n (%)
|
54 (28.6)
|
3 (33.3)
| |
|
Three, n (%)
|
55 (29.1)
|
4 (44.5)
| |
|
Stenosis of LMT, n (%)
|
15 (7.9)
|
2 (22.2)
|
NS
|
|
Multi-vessel, n (%)
|
112 (59.3)
|
8 (88.9)
|
NS
|
|
Target lesion
|
NS
|
|
LAD, n (%)
|
97 (51.3)
|
4 (44.5)
| |
|
LCX, n (%)
|
32 (16.9)
|
0 (0.0)
| |
|
RCA, n (%)
|
53 (28.1)
|
3 (33.3)
| |
|
LMT, n (%)
|
7 (3.7)
|
2 (22.2)
| |
|
Treatment strategy
|
NS
|
|
PCI (BMS), n (%)
|
82 (43.4)
|
4 (44.5)
| |
|
PCI (DES), n (%)
|
64 (33.9)
|
3 (33.3)
| |
|
POBA, n (%)
|
14 (7.4)
|
0 (0.0)
| |
|
CABG, n (%)
|
12 (6.3)
|
1 (11.1)
| |
|
Pharmacological therapy at discharge
|
|
Diuretics, n (%)
|
39 (20.6)
|
5 (55.6)
|
0.03
|
|
Anti-platelets, n (%)
|
188 (99.5)
|
9 (100)
|
NS
|
|
Anti-coagulants, n (%)
|
15 (7.9)
|
2 (22.2)
|
NS
|
|
CE inhibitor or ARB, n (%)
|
134 (70.9)
|
7 (77.8)
|
NS
|
|
Beta-blocker, n (%)
|
133 (70.4)
|
6 (66.7)
|
NS
|
|
Calcium-channel blocker, n (%)
|
52 (27.5)
|
1 (11.1)
|
NS
|
|
Statin, n (%)
|
171 (90.5)
|
6 (66.7)
|
NS
|
|
Oral hypoglycemic agents, n (%)
|
20 (10.6)
|
2 (22.2)
|
NS
|
|
Sulfonylurea, n (%)
|
5 (2.7)
|
1 (11.1)
|
NS
|
|
Alpha-glucosidase inhibitor, n (%)
|
9 (4.8)
|
0 (0.0)
|
NS
|
|
DPP-4 inhibitor, n (%)
|
8 (4.2)
|
2 (22.2)
|
NS
|
|
Metformin, n (%)
|
4 (2.1)
|
0 (0.0)
|
NS
|
|
Pioglitazone, n (%)
|
6 (3.2)
|
0 (0.0)
|
NS
|
|
Glinide, n (%)
|
0 (0.0)
|
0 (0.0)
|
NS
|
|
Insulin, n (%)
|
2 (1.1)
|
0 (0.0)
|
NS
|
|
Inotropic agents, n (%)
|
4 (2.1)
|
0 (0.0)
|
NS
|
